Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enzon CFO

Executive Summary

Enzon promotes Exec VP-Strategic Planning & Corporate Communications Craig Tooman to CFO. Before joining Enzon in January, Tooman served as Ilex' senior VP-strategic planning & corporate communications, where he was involved in the company's sale to Genzyme. Tooman's former boss, former Ilex CEO Jeffrey Buchalter, is CEO of Enzon (1"The Pink Sheet" Jan. 3, 2005, In Brief)...

You may also be interested in...



Enzon CEO is former Ilex head

Former Ilex CEO Jeffrey Buchalter joins Enzon as chief executive. Buchalter will continue to serve as chairman of Enzon's board of directors, a role he has held since September. Genzyme completed its acquisition of Ilex Dec. 21. Buchalter previously held positions at Pharmacia, Wyeth, and Schering-Plough...

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel